109 related articles for article (PubMed ID: 139029)
21. [T and B lymphocytes. I. Assessment in leukaemia and lymphoma (author's transl)].
Jamra M; Pozzi DH; Musatti CC; Tolnai ME; Figueiredo Mendes N
Sangre (Barc); 1975; 20(3):273-87. PubMed ID: 1081740
[No Abstract] [Full Text] [Related]
22. [Immunologic phenotyping of cutaneous lymphomas].
Kaudewitz P; Burg G; Smolle J; Braun-Falco O
Hautarzt; 1986 Dec; 37(12):647-55. PubMed ID: 2880828
[TBL] [Abstract][Full Text] [Related]
23. [Clinical, cytological and immunological analysis of T-cell type lymphoid malignancies: a classification of T-cell type lymphoid malignancy (author's transl)].
Shimoyama M; Minato K
Rinsho Ketsueki; 1979 Sep; 20(9):1056-69. PubMed ID: 316018
[No Abstract] [Full Text] [Related]
24. Patterns of cutaneous lymphomas. Histological, enzyme cytochemical, and immunological typing of lymphoreticular proliferations in the skin.
Burg G; Braun-Falco O; Hoffmann-Fezer G; Rodt H; Schmoeckel C
Dermatologica; 1978; 157(5):282-91. PubMed ID: 150349
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders.
Lutzner M; Edelson R; Schein P; Green I; Kirkpatrick C; Ahmed A
Ann Intern Med; 1975 Oct; 83(4):534-52. PubMed ID: 126656
[TBL] [Abstract][Full Text] [Related]
26. [Sézary syndrome. Clinical, immunological and proliferative kinetics].
Marosi L; Hofer F; Schwarzmeier J; Konrad K; Knapp W; Radaskiewicz T
Acta Med Austriaca; 1979; 6(5):237-40. PubMed ID: 318012
[TBL] [Abstract][Full Text] [Related]
27. [T and b lymphocytes. II. Sequential valuation in the course of leukaemia and lymphoma (author's transl)].
Pozzi DH; Jamra M; Musatti CC; Tolnai ME; Figueiredo Mendes N
Sangre (Barc); 1975; 20(3):311-22. PubMed ID: 1081741
[No Abstract] [Full Text] [Related]
28. [Membrane markers in chronic lymphoproliferative diseases].
Matutes E; San Miguel JF; Catovsky D
Med Clin (Barc); 1983 Mar; 80(7):334-50. PubMed ID: 6406774
[No Abstract] [Full Text] [Related]
29. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
30. [Malignant mediastinal lymphoblastic lymphoma with t-cell ALL (author's transl)].
Gaedicke G; Winkler K; Petersen N; Stein H; Landbeck G
Klin Padiatr; 1977 Jan; 189(8):31-6. PubMed ID: 300129
[TBL] [Abstract][Full Text] [Related]
31. Adult T-cell leukemia-lymphoma-related diseases in the Nagasaki District.
Kinoshita K; Amagasaki T; Yamada Y; Ikeda S; Momita S; Toriya K; Kamihira S; Ichimaru M
Jpn J Clin Oncol; 1983; 13 Suppl 2():215-30. PubMed ID: 6603530
[TBL] [Abstract][Full Text] [Related]
32. The role of immunologic aberrations in the pathogenesis of lymphoma; with particular reference to mycosis fungoides and exfoliative erythroderma.
Bierman SM
Arch Dermatol; 1968 Jun; 97(6):699-711. PubMed ID: 4232349
[No Abstract] [Full Text] [Related]
33. [Introduction to the modern classifications of the non-Hodgkin malignant lymphomas (author's transl)].
Heimann R; Van den Heule B
Dermatologica; 1978; 157(6):345-56. PubMed ID: 309837
[TBL] [Abstract][Full Text] [Related]
34. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibody against a membrane antigen characterizing leukemic human B-lymphocytes.
Forster HK; Gudat FG; Girard MF; Albrecht R; Schmidt J; Ludwig C; Obrecht JP
Cancer Res; 1982 May; 42(5):1927-34. PubMed ID: 6175400
[TBL] [Abstract][Full Text] [Related]
36. [Molecular analysis in 23 patients with T-lymphomas].
Santos M; Robledo M; Echezarreta G; Rivas C; Santón A; Benítez J
Sangre (Barc); 1991 Apr; 36(2):113-6. PubMed ID: 1866650
[TBL] [Abstract][Full Text] [Related]
37. Macrophage inhibitor factor (MIF) in cutaneous lymphoproliferative diseases.
Umbert P; Belcher RW; Winkelmann RK
Br J Dermatol; 1976 Nov; 95(5):475-80. PubMed ID: 136265
[TBL] [Abstract][Full Text] [Related]
38. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in the cutaneous T cell lymphomas.
Edelson RL
Bull Cancer; 1977; 64(2):209-24. PubMed ID: 303131
[TBL] [Abstract][Full Text] [Related]
40. [History of 2 cells in T cell lymphomas and leukemias: the cerebriform Lutzner cell in Sézary syndrome and the polylobulated or polypetaloid cell in acute T cell lymphoma/leukemia].
Lutzner MA
Hautarzt; 1985 Dec; 36(12):657-62. PubMed ID: 3003011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
